Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Peter Caldwell

Podiatrist Cedar Rapids, IA Doctor of Podiatric Medicine

NPI 1861479727 CMS profile 84665

1700 1St Ave Ne, Cedar Rapids, IA 52402

Open in the dashboard

General payments

$7,639

86 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Peter Caldwell of Cedar Rapids, IA is reported in the CMS Open Payments database as having received $7,639 across 86 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $382 18
2024 General $350 10
2023 General $1,077 13
2022 General $83 1
2020 General $2,085 21
2019 General $3,661 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Peter Caldwell
  • Podiatrist median
  • Middle half of Podiatrist
  • National median

In program year 2025, general payments to Peter Caldwell were reported at $382. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.

Show as a table
Year Peter Caldwell Podiatrist median Middle half National median
2019 $3,661 $196 $72–$601 $163
2020 $2,085 $118 $38–$335 $114
2021 $0 $169 $57–$573 $132
2022 $83 $220 $74–$782 $149
2023 $1,077 $208 $71–$635 $160
2024 $350 $237 $87–$681 $164
2025 $382 $260 $94–$777 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Arthrex, Inc. $5,456 35 payments
  2. Wardlow Enterprises $1,024 15 payments
  3. Stryker Corporation $583 28 payments
  4. Arteriocyte Medical Systems, Inc. $311 2 payments
  5. Zimmer Biomet Holdings, Inc. $230 3 payments
  6. AbbVie, Inc. $26 1 payment
  7. Orthofix Medical, Inc. $9 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Education $3,234 4 payments
  2. Food and Beverage $2,457 74 payments
  3. Travel and Lodging $1,948 8 payments
Products named General payments · program years 2019–2025
  1. Magellan $214 1 payment
  2. Nextremity ArcusTM $178 2 payments
  3. AUGMENT INJECTABLE $123 7 payments
  4. InFlux $98 1 payment
  5. FUSEFORCE $83 1 payment
  6. ANCHORAGE $64 1 payment
  7. SMART TOE $61 4 payments
  8. EASYFUSE $52 3 payments
  9. Stratum Foot Plating System $51 1 payment
  10. DISTAL EXTREMITIES IMPLANTS SOFT TISSUE FIBERTAK $50 1 payment
  11. Other $274 17 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

639

Median for Podiatry: 160

Drug cost

$6,006

Median for Podiatry: $2,368

Branded share of claims

23.2%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Neomycin-Polymyxin-Hydrocort Neomycin/Polymyxin B/Hydrocort Brand 35 $1,965
Methylprednisolone Generic 156 $912
Allopurinol Generic 22 $694
Terbinafine Hcl Generic 62 $507
Gabapentin Generic 20 $488
Celecoxib Generic 13 $215
Cephalexin Generic 63 $211
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 34 $174
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 26 $171
Doxycycline Monohydrate Generic 13 $162

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 51 billing codes

Paid by Medicare

$86,628

Of which drugs: $155

Medicare patients

422

Average age 74

Services billed

1,543

275 women, 147 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 53%
Diabetes 31%
Ischemic heart disease 27%
Chronic kidney disease 23%
Depression 22%
Osteoporosis 18%
Atrial fibrillation 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 75 207 $155

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

86 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist in Iowa

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record